A combination of erdafitinib and anti-PD1 (programmed cell death protein 1) therapy in an indigenous FGFR2K660N/p53mutant lung cancer mouse model demonstrated that combination treatment led to significant tumor regression and improved survival when compared to either treatment alone [151]. This evidence concerns the gene PDCD1 and lung carcinoma.